Genprex (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China

July 28, 2023 13:02:10
  • Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers
  • The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda
  • The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets
  • The granted patents, three Fast Track Designations, and positive preclinical and clinical data are poised to help the company accelerate its clinical development of REQORSA in its various development programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China – Genprex China Patent No: 201780076886.X – from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company’s drug candidate REQORSAI immunogene therapy in combination with PD-1 antibodies, such as KeytrI(R), to treat cancers (https://ibn.fm/AD3iX).

The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed after…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.